Elenae Therapeutics, Inc.

AI-Guided LNA Mixmer Medicines for Extrahepatic RNA Targets

health AIbiotechmedtecholigonucleotide therapeutics

StageConflicting information: sources report the company as having a corporate round while another source labels it as unfunded.

Founded2021

Employees2

LocationBerkeley, CA

Business modelB2B, partnerships/licensing

About

Elenae Therapeutics, Inc. is a platform RNA Medicine company with cutting-edge AI-designed antisense oligonucleotide (ASO) technology that can target and penetrate tissues not previously thought accessible to ASOs, including heart, skeletal muscle, retina, and lung, with an excellent safety profile. Elenae is initially targeting microRNAs identified as major pathological contributors to several aging-related diseases that limit healthspan (heart failure, dry age-related macular degeneration (AMD), and aging-related sarcopenia), as well as rare diseases such as Duchenne and Becker muscular dystrophies. The modality is based on locked nucleic acid (LNA) ASO mixmers with a phosphorothioate (PS) backbone, delivered once-weekly to once-monthly subcutaneously in saline. There is strong efficacy and safety data in mice, pigs and/or NHPs for all indications. Elenae was founded in 2021 by Anders M. Näär, PhD, Professor of Metabolic Biology at University of California, Berkeley. Elenae is housed in the Bakar Labs biotech incubator next to the UC Berkeley campus. Prof. Näär is on leave of absence and serving as full time CEO, and an ASO drug development team is in place.

Product

Value proposition: AI-guided design of steric-blocking LNA ASO mixmers for disease-driving RNA biology with extrahepatic pharmacology, enabling targetable RNA medicine campaigns and partner-ready programs
Target customers: Biotech and pharmaceutical companies seeking RNA-targeted therapeutics; potential research partners

Founders

Anders M. Näär — Founder & CEO
Sakari Kauppinen — Founder

Products

AI-guided LNA mixmer design platformsteric-blocking LNA ASO mixmersRNA-targeting medicinal chemistry platform

Key features

AI-guided design engine for LNA mixmersprospective design benchmarkingmulti-tissue pharmacology platformtarget selection and tissue-access strategyfractionated synthesis-ready library prioritizationexon-skipping, splice modulation, anti-miR and translation modulation capabilities

Technologies

AI-driven ASO designLNA mixmer chemistrysteric-blocking ASOsmulti-omics tissue-context analysispharmacology profiling

Integrations

platform integrations with internal pipelines or partnering workflows (unspecified)

Target conditions

RNA-related diseases/conditions affecting transcriptome regulation

Care settings

laboratorycompany R&D settingclinical development (future)

Partnerships

Lilly Creyon Bio collaboration (multi-target deal potentially exceeding $1B)AstraZeneca Algen collaboration in functional genomicsRegulus, Novo Nordisk, Novartis related signals (biotech validations)

Traction metrics

Prospective design benchmark: 2 of 9 designed molecules outperformed a reference (from text)signal of validation through external collaborations

Investors

RESI Innovator's Pitch Challenge

News

Companies - Bakar Bio Labs · 2025-09-04T00:00:00.000Z
Anders Naar posted this - LinkedIn · 2026-01-09T00:00:00.000Z
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics · 2025-07-12T10:54:05.000Z
Eilean Therapeutics Presents Novel, Selective, Brain-Permeable CDK2 Inhibitor for Treatment of CCNE1-Dependent Cancers — Eilean Therapeutics · 2025-10-16T12:00:00.000Z
About Eliaz Therapeutics - Eliaz Therapeutics · 2026-05-14T14:03:19.000Z
EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference — Eilean Therapeutics · 2025-10-13T19:49:18.000Z